ArticleJournal of the National Cancer Institute2020
Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
Article in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Oncotype DX in clinical practice: impact on treatment decisions and healthcare system economy.Pathologica · 2025Article
- A review on the role of deep eutectic solvents in mango (RSC advances · 2025Review
- Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.NPJ breast cancer · 2024Article
- A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer.Nature medicine · 2024Article
- Machine learning improves prediction of clinical outcomes for invasive breast cancers.Nature medicine · 2024Article
- Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.Breast disease · 2024Article
- Evaluation of different imaging modalities for axillary lymph node staging in breast cancer patients to provide a personalized and optimized therapy algorithm.Journal of cancer research and clinical oncology · 2023Article
- Anticancer role of mango (Mangifera indica L.) peel and seed kernel extracts against 7,12- dimethylbenz[a]anthracene-induced mammary carcinogenesis in female rats.Scientific reports · 2023Article
- Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence.NPJ breast cancer · 2023Article
- Overview of non-coding RNAs in breast cancers.Translational oncology · 2022Review
- The use of genomic assays reduces rates of chemotherapy: a single-institution experience.Irish journal of medical science · 2022Article
- Oncotype DX Recurrence Score in premenopausal women.Therapeutic advances in medical oncology · 2022Review
- Construction of an immunogenic cell death-based risk score prognosis model in breast cancer.Frontiers in genetics · 2022Article
- Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.Breast cancer research and treatment · 2021Observational
- Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.British journal of cancer · 2021Review
- Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.Breast (Edinburgh, Scotland) · 2020Article
- The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.Cancer medicine · 2020Article
- Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.Journal of the National Cancer Institute · 2020Article
- Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications.Journal of the National Cancer Institute. Monographs · 2020Review
- Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.Journal of the National Cancer Institute · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTAILORx demonstrated that women with node-negative, hormone receptor-positive, HER2-negative breast cancers and Oncotype DX recurrence scores (RS) of 0-25 had similar 9-year outcomes with endocrine vs chemo-endocrine therapy; evidence for women aged 50 years and younger and RS 16-25 was less clear. We estimated how expected changes in practice following the trial might affect US costs in the initial 12 months of care (initial costs).
methodsData from Surveillance, Epidemiology, and End Results (SEER), SEER-Medicare, and SEER-Genomic Health Inc datasets were used to estimate Oncotype DX testing and chemotherapy rates and mean initial costs pre- and post-TAILORx (in 2018 dollars), assuming all women received Oncotype DX testing and score-suggested therapy posttrial. Sensitivity analyses tested the impact on costs of assumptions about compliance with testing and score-suggested treatment and estimation methods.
resultsPretrial mean initial costs were $2.816 billion. Posttrial, Oncotype DX testing costs were projected to increase from $115 to $231 million and chemotherapy use to decrease from 25% to 17%, resulting in initial care costs of $2.766 billion, or a net savings of $49 million (1.8% decrease). A small net savings was seen under most assumptions. The one exception was if all women aged 50 years and younger with tumors with RS 16-25 elected to receive chemotherapy, initial care costs could increase by $105 million (4% increase).
conclusionsPersonalizing breast cancer treatment based on tumor genetic profiles could result in small cost decreases in the initial 12 months of care. Studies are needed to evaluate the long-term costs and nonmonetary benefits of personalized cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.